What Researchers Did
Researchers conducted a prospective, randomized, cross-over trial with 50 diabetic patients with non-healing ulcers to investigate the effect of N-acetylcysteine (NAC) on hyperbaric oxygen therapy (HBO2) outcomes by measuring various biomarkers.
What They Found
During hyperbaric oxygen therapy (HBO2), 17 patients (34%) showed an insufficient increase in peri-wound oxygenation (TcPO2), accompanied by decreased total anti-oxidant status (TAOS) and nitric oxide (NO), and increased malondialdehyde (MDA). Administering N-acetylcysteine (NAC) attenuated these negative changes, improving HBO2 outcomes and resulting in a 75% cure rate in this subgroup, compared to an 82% cure rate in the 66% of patients who had sufficient TcPO2 increase.
What This Means for Canadian Patients
For Canadian diabetic patients with non-healing ulcers receiving HBO2, N-acetylcysteine (NAC) could serve as a beneficial adjunct therapy. It may help improve wound oxygenation and healing, particularly in those who initially show a poor response to HBO2 alone.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada nor involved Canadian researchers or participants.
Study Limitations
The study's findings are based on a relatively small sample size of 50 patients and the long-term efficacy of NAC beyond the immediate treatment period was not fully explored.